Patents Examined by A. M. Davenport
  • Patent number: 5840843
    Abstract: A synthetic HIV-1-based polypeptide as well as methods for treating HIV-1 infections are provided herein. The polypeptide of the present invention has an amino acid sequence substantially corresponding to a specified region of the HIV-1.sub.IIIB virus. The polypeptide of the present invention may be administered in effective amounts for preventing and treating HIV-1 infections. The polypeptide is useful for inhibiting the replication of the HIV-1 virus as well as HIV-1-mediated cytopathogenesis and cell fusion at levels which are within acceptable ranges of cytotoxicity.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: The New York Blood Center
    Inventors: Shibo Jiang, Kang Lin, A. Robert Neurath
  • Patent number: 5834433
    Abstract: A method for controlling the growth of tumor tissues, especially small cell lung. Treatment comprises administering to a patient in need thereof, an effective amount of a bombesin/GRP type inhibitor.Antagonists of bombesin/GRP which are derivatives of naturally occurring bombesin/GRP possessing a thiomethylene or methylene sulfoxide bond connecting the two amino acids on the carboxy terminal end is modified are described. The antagonism is confirmed using conventional competitive binding and biochemical assays as well as conventional physiological tests and the use of these derivatives in a variety of conditions in which bombesin/GRP is implicated is also described.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: November 10, 1998
    Assignee: Merrell Pharmaceuticals Inc.
    Inventor: John L. Krstenansky
  • Patent number: 5834431
    Abstract: The present invention provides des-Arg.sup.9 bradykinin analogs which are selective B1 receptor antagonists.
    Type: Grant
    Filed: September 8, 1995
    Date of Patent: November 10, 1998
    Assignees: Cortech, Inc., University of Colorado
    Inventors: John M. Stewart, Eric T. Whalley, Lajos Gera
  • Patent number: 5830856
    Abstract: This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: November 3, 1998
    Assignee: Diatide, Inc.
    Inventors: Richard T. Dean, John Lister-James, Edgar R. Civitello, William McBride
  • Patent number: 5824645
    Abstract: A method of producing analgesia in nociceptive and neuropathic pain is disclosed. The method includes administering to a subject an omega conopeptide which is characterized by its ability to (a) inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue. Also disclosed are novel omega conotoxin peptides effective in producing analgesia.
    Type: Grant
    Filed: November 1, 1996
    Date of Patent: October 20, 1998
    Assignee: Neurex Corporation
    Inventors: Alan Justice, Tejinder Singh, Kishor Chandra Gohil, Karen L. Valentino, George P. Miljanich
  • Patent number: 5821330
    Abstract: A peptide having affinity with inflammation is disclosed, which contains at least one of the following amino acid sequences:LLGGPS (SEQ ID NO:1),LLGGPSV (SEQ ID NO:2),KEYKAKVSNKALPAPIEKTISK (SEQ ID NO:3),KEYKCKVSNKALPAPIEKTISK (SEQ ID NO:4),KTKPREQQYNSTYR (SEQ ID NO:5), andKTKPREQQYNSTYRVV (SEQ ID NO:6),wherein A, C, E, G, I, K, L, N, P, Q, R, S, T, V, and Y represent amino acid residues expressed by standard one-letter symbols. According to the present invention, a peptide and its chemically modified substances, radioactive metal labeled peptides derived therefrom, and radioactive diagnostics comprising such peptide are provided, which are useful for imaging inflammation region and easy in preparation handling, and accumulate at inflammation site immediately after administration while being excellent in clearance into urine. The imaging is possible in several ten minutes after administration.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: October 13, 1998
    Assignee: Nihon Medi-Physics Co., Ltd.
    Inventors: Yoshitoshi Itaya, Koichi Hanaoka, Yoshifumi Shirakami
  • Patent number: 5817629
    Abstract: Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administration of peptide MBP75-95, either as a single dose, or as repeated injections for periods up to 10 weeks, produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP75-95 resulted in significant decline of F and B CSF anti-MBP levels over a period of one month.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: October 6, 1998
    Assignee: The Governors of the University of Alberta
    Inventors: Kenneth G. Warren, Ingrid Catz
  • Patent number: 5811394
    Abstract: The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides which bind technetium-99m and which can be targeted to specific sites within a mammalian body.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 22, 1998
    Assignee: Diatide, Inc.
    Inventor: Richard T. Dean
  • Patent number: 5807828
    Abstract: Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 15, 1998
    Assignee: COR Therapeutics, Inc.
    Inventor: Robert M. Scarborough
  • Patent number: 5807825
    Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formulaR.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO--wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4.sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 15, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Robert M. Scarborough, David Lawrence Wolf, Israel F. Charo
  • Patent number: 5807827
    Abstract: Novel peptides of the invention are dynorphin analogues and have similar activity to endogenous dynorphin, but are des-Tyr or des-Tyr-Gly with respect to endogenous dynorphin and have at least seven amino acid residues. The novel peptides have therapeutic uses, such as administration to a host tolerant to a narcotic analgesic in order to potentiate activity of the narcotic analgesic and/or to block withdrawal symptoms.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: September 15, 1998
    Assignee: Des-Tyr Dynorphin Partnership
    Inventors: Nancy M. Lee, Horace H. Loh, Akira E. Takemori
  • Patent number: 5807982
    Abstract: The present invention relates to a method for purifying heparin into two subspecies of molecules, one which binds transforming growth factor-.beta. (TGF-.beta.), and another which does not. The method involves using a peptide, immobilized on a chromatography substrate, that is homologous to the heparin-binding region of TGF-.beta. and allowing the heparin to contact the immobilized peptide for a sufficient time to cause binding. The fraction of heparin which does not bind to the peptide retains its activity as an anticoagulant but is devoid of the ability to bind TGF-.beta..
    Type: Grant
    Filed: April 29, 1991
    Date of Patent: September 15, 1998
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Timothy A. McCaffrey, Domenick J. Falcone
  • Patent number: 5804554
    Abstract: Polypeptides isolated from the venom of the Filistata hibernalis spider block calcium channels in cells of various organisms and are useful in blocking said calcium channels in cells, per se, in the treatment of calcium channel-mediated diseases and conditions and in the control of invertebrate pests.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: September 8, 1998
    Assignee: Pfizer Inc.
    Inventors: Deane M. Nason, II, Steven D. Heck, Robert T. Ronau, Nicholas A. Saccomano, Robert A. Volkmann
  • Patent number: 5804557
    Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.
    Type: Grant
    Filed: September 24, 1996
    Date of Patent: September 8, 1998
    Assignee: Genentech, Inc.
    Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
  • Patent number: 5795867
    Abstract: Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 18, 1998
    Assignee: COR Therapeutics, Inc.
    Inventor: Robert M. Scarborough
  • Patent number: 5795864
    Abstract: Disclosed are formulations effective to stabilize omega conotoxin peptide preparations at elevated temperatures. Novel omega conopeptides also form part of the invention.
    Type: Grant
    Filed: June 27, 1995
    Date of Patent: August 18, 1998
    Assignee: Neurex Corporation
    Inventors: Gary Arthur Amstutz, Stephen Scott Bowersox, Kishorchandra Gohil, Peter Isadore Adriaenssens, Ramasharma Kristipati
  • Patent number: 5795957
    Abstract: Novel peptides comprising D-2-alkyltryptophan, useful for promoting growth hormone release, compositions comprising such peptides and methods of using such compositions are described. In a preferred embodiment of the invention, the D-2-alkyl tryptophan is D-2-methyltryptophan.
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: August 18, 1998
    Inventor: Romano Deghenghi
  • Patent number: 5795868
    Abstract: Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: August 18, 1998
    Assignee: COR Therapeutics, Inc.
    Inventor: Robert M. Scarborough
  • Patent number: 5789383
    Abstract: Bradykinin antagonists and their physiologically tolerated salts are suitable for the treatment or prophylaxis of virus diseases.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: August 4, 1998
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Klaus Wirth, Irvin Winkler, Fred Lembeck, Gerhard Breipohl, Stephan Henke, Jochen Knolle
  • Patent number: 5786333
    Abstract: An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolated and purified PAI from several of these active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K*-(G/Sar)-D wherein K* is a modified lysyl residue of the formulaR.sup.1.sub.2 N(CH.sub.2).sub.4 CHNHCO--wherein each R.sup.1 is independently H, alkyl(1-6C) or at most one R.sup.1 is R.sup.2 --C.dbd.NR.sup.3 wherein R.sup.2 is H, alkyl(1-6C), phenyl or benzyl, or is NR.sup.4 .sub.2 in which each R.sup.4 is independently H or alkyl(1-6C) and R.sup.3 is H, alkyl(1-6C), phenyl or benzyl, or R.sup.2 --C.dbd.NR.sup.3 is a radical selected from the group consisting of: ##STR1## where m is an integer of 2-3, and each R.sup.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 28, 1998
    Assignee: COR Therapeutics, Inc.
    Inventors: Robert M. Scarborough, David Lawrence Wolf, Israel F. Charo